A double blind placebo controlled trial of recombinant tissue plasminogen activator in the treatment of digital ischemia in systemic sclerosis

Klimiuk, P.S.; Kay, E.A.; Illingworth, K.J.; Gush, R.J.; Taylor, L.J.; Baker, R.D.; Perkins, C.; Jayson, M.I.

Journal of Rheumatology 19(5): 716-720

1992


ISSN/ISBN: 0315-162X
PMID: 1613700
Document Number: 399530
The treatment of digital ischemia in systemic sclerosis remains inadequate. We report a double blind, placebo controlled trial of recombinant tissue plasminogen activator (rtPA), a potent thrombolytic agent. Ten patients received rtPA. A potent, acute fibrinolytic effect was observed. During the infusion of rtPA, improvements in skin blood flow were seen. These improvements were shortlived.

Document emailed within 1 workday
Secure & encrypted payments